Emyria Ltd (AU:EMD)
ASX:EMD
Want to see AU:EMD full AI Analyst Report?
EMD Stock Chart & Stats
AU$0.06
>-AU$0.01(-2.94%)
At close: 4:00 PM EST
AU$0.06
>-AU$0.01(-2.94%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.08
Previous CloseN/A
Volume148.47K
Average Volume (3M)4.06M
Market Cap
AU$33.07M
Enterprise ValueAU$18.62M
Total Cash (Recent Filing)AU$10.50M
Total Debt (Recent Filing)AU$1.06M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding806,561,040
10 Day Avg. Volume2,903,931
30 Day Avg. Volume4,056,978
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.37
Price to Sales (P/S)9.01
P/FCF Ratio-4.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$5.90M
Bulls Say, Bears Say
Bulls Say
Service-based Revenue ModelA fee-for-service model tied to clinical care and contracted research creates durable, transaction-based revenue streams. These services produce recurring billing when utilization and trial activity are sustained and are less dependent on product commercialization timelines, supporting near-term operating receipts.
Manageable Leverage On Balance SheetLow debt relative to equity provides financial flexibility to absorb operating losses or fund additional clinical activity without heavy interest burdens. This capital structure supports the ability to raise incremental funds or extend runways while limiting immediate solvency pressure over the medium term.
Focus On Mental Health And Psychedelic TherapiesPositioning at the intersection of mainstream mental health care and emerging psychedelic-assisted research aligns with structural demand growth and expanding clinical validation pathways. The combined clinical services and research capability can create integrated long-term value as therapies advance through trials and regulatory acceptance.
Bears Say
Declining Revenue And Negative MarginsA material year-over-year revenue decline coupled with negative gross and operating margins indicates the core business currently fails to cover direct and overhead costs. Persisting declines and sustained unprofitability erode reinvestment capacity, threaten program funding, and increase reliance on external financing over the medium term.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flows signify the company is not generating internal funds to support operations or clinical programs. Even with strong percentage growth in FCF, absolute deficits require capital injections to sustain trials and services, creating dilution or refinancing risk and limiting strategic optionality.
Negative Return On EquityNegative ROE reflects that shareholder capital is being consumed rather than earning returns, undermining investor confidence and making future equity raises more dilutive. Persistently negative ROE also signals operational inefficiencies and poor capital allocation that can impede long-term growth and competitiveness.
Emyria Ltd News
EMD FAQ
What was Emyria Ltd’s price range in the past 12 months?
Emyria Ltd lowest share price was AU$0.02 and its highest was AU$0.08 in the past 12 months.
What is Emyria Ltd’s market cap?
Emyria Ltd’s market cap is AU$33.07M.
When is Emyria Ltd’s upcoming earnings report date?
Emyria Ltd’s upcoming earnings report date is Sep 01, 2026 which is in 80 days.
How were Emyria Ltd’s earnings last quarter?
Emyria Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Emyria Ltd overvalued?
According to Wall Street analysts Emyria Ltd’s price is currently Overvalued.
Does Emyria Ltd pay dividends?
Emyria Ltd does not currently pay dividends.
What is Emyria Ltd’s EPS estimate?
Emyria Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emyria Ltd have?
Emyria Ltd has 806,561,040 shares outstanding.
What happened to Emyria Ltd’s price movement after its last earnings report?
Emyria Ltd reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.704%.
Which hedge fund is a major shareholder of Emyria Ltd?
Currently, no hedge funds are holding shares in AU:EMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Emyria Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:EMD Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.66%
12-Months-Change
Fundamentals
Return on Equity
-52.26%
Trailing 12-Months
Asset Growth
170.82%
Trailing 12-Months
Company Description
Emyria Ltd
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs. Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.
Technical Analysis
Options Prices
Currently, No data available
---